Related Experiment Videos

Determining the duration of therapy for patients with community-acquired pneumonia

Nikole M Scalera1, Thomas M File

  • 1Summa Health System, 75 Arch St. Suite 506, Akron, OH, 44304, USA, scaleran@summahealth.org.

Current Infectious Disease Reports
|February 28, 2013
PubMed

Insights

Shorter antibiotic courses for community-acquired pneumonia (CAP) are effective and safe. Utilizing biomarkers like procalcitonin and antibiotic stewardship teams can optimize CAP treatment duration.

Area of Science:

  • Infectious Diseases
  • Antimicrobial Therapy
  • Clinical Microbiology

Background:

  • Community-acquired pneumonia (CAP) is frequently treated with 7-14 day antibiotic courses.
  • Emerging evidence suggests shorter durations may be effective.
  • Antimicrobial resistance is a growing global health concern.

Purpose of the Study:

  • To evaluate the efficacy and safety of shorter antibiotic treatment durations for CAP.
  • To explore the role of biomarkers in guiding CAP therapy.
  • To assess the impact of antibiotic stewardship on treatment optimization.

Main Methods:

  • Systematic reviews of existing literature.
  • Analysis of clinical trial data on CAP treatment.
  • Biomarker-guided therapy protocols (e.g., procalcitonin).
  • Implementation of antibiotic stewardship team interventions.

Main Results:

  • Shorter antibiotic courses (<7 days) demonstrate comparable efficacy and safety to longer durations for CAP.
  • Procalcitonin use effectively guides therapy duration without compromising mortality or cure rates.
  • Antibiotic stewardship programs facilitate successful reduction in CAP treatment length.

Conclusions:

  • Optimized antimicrobial selection and shorter treatment durations (<7 days) are recommended for CAP.
  • Biomarker utilization (procalcitonin) and antibiotic stewardship are key to reducing therapy length.
  • Shorter courses improve patient outcomes and mitigate antimicrobial resistance development.

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...